Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TTI-621 + pegylated interferon-α2a
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Intratumoral
01
Overview
TTI-621 is a recombinant fusion protein that combines the N-terminal CD47-binding domain of human signal regulatory protein alpha (SIRPα) with the Fc region of human IgG1. It acts as a decoy receptor for CD47, blocking the "do not eat" antiphagocytic signal delivered to macrophages by tumor cells, thereby promoting macrophage-mediated phagocytosis and activation of natural killer (NK) cells. Pegylated interferon-alpha 2a is a modified form of interferon-alpha with polyethylene glycol attached to improve its pharmacokinetics and tolerability; it acts as an immunomodulatory cytokine. The combination aims to enhance innate and adaptive immune responses against tumors, leveraging both checkpoint blockade (via TTI-621) and immune stimulation (via pegylated IFN). TTI-621 was developed by Trillium Therapeutics for use in hematologic malignancies and solid tumors[3][5][6][8].
- Other names
- pegylated interferon-alpha 2aPEG-interferon alpha 2a
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on TTI-621 + pegylated interferon-α2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TTI-621 + pegylated interferon-α2a.